|
VIT B6 REQUIREMENT IS INCREASED BY THE DRUG
|
BARBITURATES INCREASE ITS METABOLISM LEADING TO REDUCED EFFICACY
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
GRISEOFULVIN INCREASES RATE OF METABOLISM OF THE DRUG LEADING TO REDUCED PLASMA LEVELS
|
FOLIC ACID DEFICIENCY MAY PRECIPITATE WITH CONCURRENT USE
|
TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
ORAL CONTRACEPTIVES, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
CONCURRENT USE MAY RENDER ORAL CONTRACEPTIVE LESS EFFECTIVE
|
CONCURRENT USE MAY RENDER ORAL CONTRACEPTIVE LESS EFFECTIVE
|
CONCURRENT USE MAY RENDER ORAL CONTRACEPTIVE LESS EFFECTIVE
|
CONCURRENT USE MAY RENDER ORAL CONTRACEPTIVE LESS EFFECTIVE
|
CONCURRENT USE MAY RENDER ORAL CONTRACEPTIVE LESS EFFECTIVE
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
OESTROGENS REDUCE THE HYPOGLYCEMIC EFFECTS OF ANTIDIABETICS
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
HYPOGLYCEMIC EFFECT IS REDUCED BY THE DRUG
|
PROGESTERONES TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
ORAL CONTRACEPTIVES ON CONCURRENT USE INCREASE THE RISK OF THROMBOSIS
|
TIZANIDINE PLASMA CLEARANCE IS REDUCED BY ORAL CONTRACEPTIVES
|
TRIPTORELIN RESPONSE MAY ALTER BY THE DRUGS WHICH AFFECT PITUTARY SECRETION OF GONADOTROPHINS. SEX HORMONES CAN INHIBIT GONADOTROPHIN SECRETION
|